209919-64-2Relevant articles and documents
HUMAN PLASMA KALLIKREIN INHIBITORS
-
Page/Page column 139; 141, (2015/11/02)
Disclosed are compounds of formula (I), as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2′-(methylsulfonyl)-[1,1′-b iphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa
Pinto,Orwat,Wang,Fevig,Quan,Amparo,Cacciola,Rossi,Alexander,Smallwood,Luettgen,Liang,Aungst,Wright,Knabb,Wong,Wexler,Lam
, p. 566 - 578 (2007/10/03)
Factor Xa (fXa) plays a critical role in the coagulation cascade, serving as the point of convergence of the intrinsic and extrinsic pathways. Together with nonenzymatic cofactor Va and Ca2+ on the phospholipid surface of platelets or endotheli